#USA #Ascentage Pharma #Marina Bozilenko #Debra Yu #Rockville

Ascentage Pharma Welcomes New Directors

Ascentage Pharma, a prominent player in the biopharmaceutical industry, has recently announced the addition of two distinguished individuals to its board of directors. Effective November 25, 2024, Ms. Marina S. Bozilenko and Dr. Debra Yu join as independent non-executive directors, a move that is poised to enhance the company's strategic direction and operational success in the rapidly evolving global pharma landscape.

Dr. Dajun Yang, the Chairman and CEO of Ascentage Pharma, expressed his excitement about the appointments. He stated, “I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive directors.” Their collective experience in finance, investment, and strategic management is expected to provide invaluable insights as the company advances its global innovation strategy.

Profiles of the New Directors

Ms. Marina S. Bozilenko

Ms. Bozilenko is a seasoned professional with extensive experience in the biopharmaceutical sector. Currently, she serves as the President and CEO of Biothea Pharma and holds directorship positions at Talphera, Inc. and SynAct Pharma AB. Her previous roles include managing director positions at William Blair & Co. and Bear Stearns & Co., showcasing her capability in business development and management.

A graduate of the University of Chicago, where she earned both a bachelor’s degree in biochemistry and a master’s degree in social science, Ms. Bozilenko's expertise will be a vital asset to Ascentage Pharma’s future endeavors. She has also been involved with various boards, offering strategic guidance and governance within the pharmaceutical industry.

Dr. Debra Yu

Dr. Debra Yu brings a wealth of knowledge in healthcare and operational management. Currently, she is the Chief Operating Officer and a partner at Panacea Venture and serves on the board at MeiraGTx Holdings PLC. With a noted career in investment banking for healthcare at China Renaissance Securities, Dr. Yu has facilitated numerous critical cross-border partnerships and transactions in her previous roles at LianBio and WuXi AppTec.

Dr. Yu’s academic credentials are equally impressive, having graduated with high honors in molecular biology from Princeton University and holding a Doctor of Medicine degree from Harvard Medical School. Her extensive background in venture capital in the San Francisco Bay Area and strategic roles at McKinsey & Co. and Morgan Stanley will undoubtedly propel Ascentage towards achieving its mission to address unmet clinical needs worldwide.

Ascentage Pharma’s Vision

Ascentage Pharma (6855.HK) is at a pivotal point in its growth, focused on addressing significant global health challenges, particularly malignancies. With a promising pipeline of innovative drug candidates, including leading-edge Bcl-2 inhibitors and drug development targeting key apoptosis regulators, the company is committed to enhancing its research and development capabilities.

As a leader in biopharmaceutical innovation, Ascentage has established partnerships with top global firms, including Takeda and Pfizer, securing substantial investments to expedite the development of new therapies. The appointments of Ms. Bozilenko and Dr. Yu align with the company’s goal of driving forward its strategic initiatives effectively as it navigates the competitive landscape of the pharmaceutical industry.

Ascentage Pharma is poised to make significant strides in transforming the treatment landscape for patients worldwide, and the new directors are expected to play a crucial role in this journey.